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Chronic Infection and
Coronary Atherosclerosis
Will the Hypothesis
Ever Really Pan Out?*
Joseph B. Muhlestein, MD
Murray and Salt Lake City, Utah
Although much is known about the process whereby ath-
erosclerosis develops, in many cases the underlying cause
remains unclear. Certain risk factors are well defined,
including diabetes mellitus, hypertension, hyperlipidemia,
tobacco abuse, and a positive family history (1). These risk
factors, however, combine to account for only about 50% of
the observed incidence of atherosclerosis (2). Additionally,
these risk factors generally are only associations, and the
exact mechanism by which they may contribute to the
development of atherosclerosis is not known. Certainly
other factors must also be involved.
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One proposed additional contributory participant to ath-
erosclerosis is chronic infection. Indeed, much research over
the past 20 years has associated a fairly large number of
infectious agents with atherosclerosis and its associated
complications of myocardial infarction and stroke. Some of
the most documented candidate infectious agents include
Chlamydia pneumoniae, Helicobacter pylori, Mycoplasma
pneumoniae, periodontal infections, cytomegalovirus, other
Herpes viruses, human immunodeficiency virus, and influ-
enza virus (3). The paper by Kuo et al. (4), in this issue of
the Journal, adds even another candidate infectious agent,
human papillomavirus (HPV). Other studies have also
demonstrated that exposure to a larger number of infectious
agents (ascribed the term “pathogen burden”) is associated
with a larger cardiovascular risk (5). The lines of evidence
associating chronic infection with atherosclerosis are many
and range from epidemiologic associations between sero-
positivity to various infectious agents and the prevalence or
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paper to disclose.incidence of coronary artery disease, to the actual documen-
tation of pathogenic organisms growing within atheroscle-
rotic plaque, to the demonstration by animal studies of the
acceleration of atherosclerosis after intravascular inoculation
with the proposed infectious agent.
The authors of the present study provided evidence of a
relationship between HPV and atherosclerosis by testing for
the presence of HPV DNA within vaginal swabs of 2,450
females enrolled in the National Health and Nutrition
Examination Survey (NHANES) 2003 to 2006 study. They
reported a strong association (odds ratio: 1.89 to 2.86,
depending on the absence or presence of cancer-associated
HPV types) between the presence of HPV DNA and a prior
history of myocardial infarction or stroke. Although these
results come from a large, well-documented National Insti-
tutes of Health–funded study, there are limitations that
make its results merely hypothesis generating rather than
definitive. First, the ascertainment of adverse cardiovascular
events was done simply by asking the participants if their
doctor had ever told them they had experienced either a
heart attack or stroke, thus introducing the potential for
recall bias. Second, in general, the female participants were
quite young (age 37.9 [range 20 to 59] years). Therefore, as
expected, the numbers who had experienced an adverse
cardiovascular event were very small (60 [2.5%]), which
reduces the power of the study. Additionally, the results may
not generalize to the overall group of women who experi-
ence cardiovascular events. Because cardiovascular disease
usually presents in women who are more than 60 years of
age, the ones in this study who experienced adverse events at
very young ages may have had an atypical form of athero-
sclerosis that is associated with HPV infection, but the vast
majority of cardiovascular events that occur in women later
on in life may hold no relationship to HPV infection. Third,
the study was cross sectional rather than prospective, which
disallows any inference of causality and, instead, merely
allows a conclusion of association. Fourth, no adjustment
for socioeconomic status was provided. Low socioeconomic
status has been found to be associated with both HPV
infection (6) and with cardiovascular disease (7). Since the
limitations of the study do not allow any conclusive causal
relationship between HPV and cardiovascular disease to be
drawn, but do suggest evidence of a causal relationship,
additional large prospective studies in women of all ages
should be performed to confirm or refute this report.
A large variety of chronic infectious agents has been
associated with atherosclerotic cardiovascular disease and
has been confirmed in many studies. However, despite more
than 20 years of intense research into the subject, the
proposal that chronic infectious agents participate to an
important extent in the development and progression of
atherosclerosis remains just a hypothesis, neither proven nor
disproven. This is mainly because of difficulties related to
proving Koch’s postulates directly in humans. To establish a
causative relationship between an infectious agent and a
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(8), must be individually met. First, the infectious agent
must be found in most or all the subjects in whom the
disease process is manifested. Second, when the agent is
introduced into another subject, the disease must result.
Third, the organism must be recovered from the new
subject. Because it is unethical to directly infect human
subjects to prove Koch’s postulates, other approaches to test
the hypothesis in humans have been attempted, especially
antibiotic treatment trials.
The general idea regarding antibiotic treatment trials is
that if someone with atherosclerosis is found to be chroni-
cally infected with a certain agent, antibiotic therapy tar-
geted to eradicate the offending agent will reduce the risk of
future cardiovascular events, thus proving the contribution
of the chronic infection to cardiovascular risk. Based on this
concept, and with the strong evidence linking Chlamydia
pneumoniae to cardiovascular disease, many thousands of
patients with pre-existing cardiovascular disease were en-
rolled into a variety of secondary prevention antibiotic trials.
All of these trials were negative for the prevention of future
cardiovascular events. With the difficulties associated with
attempting to eradicate chronic viral infections through
antibiotics, fewer studies with antiviral agents have been
tried. Thus far, the only treatment approach targeting a
specific infectious agent that has been effective is influenza
vaccination (9,10).
But the failure of targeted anti-infective treatments does
not necessarily mean that these infectious agents do not
contribute to the burden of cardiovascular disease. First,
thus far, all the treatment trials have targeted secondary
prevention populations. As proposed by Anderson in an
editorial in 2005 (11), the antibiotics may have been given
too late in the atherosclerotic process, at an advanced and
unmodifiable stage of the disease. Second, the antibiotics
chosen may not have been effective in eradicating the
infective agent. Certainly this may have been the case in
relationship to attempts to eradicate Chlamydia pneumoniae.
After multiple attempts were made to use azithromycin for
the secondary prevention of coronary artery disease, Gieffers
et al. (12) reported that Chlamydia pneumoniae uses mono-
cytes as a transport system for systemic dissemination and
enters a persistent state not covered by an otherwise effective
antichlamydial treatment, and therefore, prevention of vas-
cular infection by antichlamydial treatment may be prob-
lematic: circulating monocytes carrying a pathogen with
reduced antimicrobial susceptibility might initiate reinfec-
tion or promote atherosclerosis by the release of proinflam-
matory mediators.
Attacking atherosclerosis upstream may be more effective.
As noted in the previous text, the use of influenza vaccina-
tion has been effective (10). Unfortunately, other potential
infectious agents such as Chlamydia pneumoniae, cytomeg-
alovirus, and so on have been more resistant to the devel-
opment of effective vaccines. One positive aspect relating to
the newly proposed relationship between HPV and athero-sclerosis is the fact that an effective vaccine for HPV already
exists (13).
In summary, the present article adds another important
infectious candidate to the list of agents associated with the
development, progression, or destabilization of atheroscle-
rotic cardiovascular disease. This finding re-emphasizes the
potential roles that a variety of chronic infectious agents may
play in the pathogenesis of atherosclerosis. Despite setbacks
experienced in a number of clinical trials designed to treat
patients based on the “infectious hypothesis,” it still lives on,
and slowly, progress is being made. Better antibiotics are
being developed (14). A greater understanding of the
physiological link between infection and atherosclerosis is
being acquired (15). And hope now exists for methods of
earlier intervention through the use of vaccines (16). De-
spite positive treatment advances on many fronts, cardio-
vascular disease continues to afflict millions, perhaps bil-
lions, of people throughout the world. With that many
people involved, certainly, the presently expanding body of
evidence associating it with chronic infection justifies con-
tinued investment into this fascinating research area. In the
end, the infectious hypothesis of atherosclerosis may still
pan out.
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